FOSRENOL.com: For the treatment of hyperphosphatemia

Important Safety Information | Full Prescribing Information

For Patients and Caregivers

If you're a patient or caregiver, you may know hyperphosphatemia may be a condition that requires long-term treatment. To learn more about how FOSRENOL^® (lanthanum carbonate) can help keep your phosphorus levels down by taking as few as 3 tablets per day,* visit the Patients/Caregivers site.
For Health Care Professionals

If you're a health care provider, you may be aware life can be a challenge for patients with ESRD and hyperphosphatemia. Reformulated dosage strengths of calcium-free FOSRENOL^® (lanthanum carbonate) may deliver the potent efficacy your patients need with as few as 3 tablets per day.* To learn more about FOSRENOL^®, visit the Health Care Professionals site

*Dosing based on three meals per day. Number of meals per day may vary. To achieve certain doses, additional tablets may be required.
For Renal Dietitians

If you are a renal dietitian, you play a key role in caring for your patients. To help you respond to the needs of each patient, we’ve developed a site and online materials to help develop a customized treatment plan built around his or her strengths and weaknesses. To learn more, visit the Renal Dietitian site.

Important Safety Information

During clinical trials, the most common side effects of FOSRENOL^® were gastrointestinal, and included nausea, vomiting, and diarrhea. Nausea and vomiting generally lessened over time as patients continued with their treatment.

Patients who stopped treatment usually reported gastrointestinal side effects as the reason for stopping. Other side effects reported in trials included dialysis graft complications, headache, abdominal pain, and low blood pressure.

Although studies were not designed to detect differences in risk of bone fracture and mortality, there were no differences demonstrated in patients treated with FOSRENOL^® compared to alternative therapy for up to 3 years.

The duration of treatment exposure and time of observation in the clinical program were too short to conclude that FOSRENOL^® does not affect the risk of bone fracture or mortality beyond 3 years.

While lanthanum has been shown to accumulate in the GI tract, liver, and bone, in animals, the clinical significance in humans is unknown.

If you suffer from acute stomach ulcer, colon inflammation and colon ulcers, Crohn's disease, or bowel obstruction, it is important to know that patients with these conditions were not included in FOSRENOL^® clinical studies — please discuss with your doctor.

Don't take FOSRENOL^® if you are nursing or pregnant, or if you are under 18 years of age.

This site is strictly intended for US residents and is governed solely by US laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

FOS1726 1/15/2008

For Patients and Caregivers

For Health Care Professionals

For Renal Dietitians